HCW Biologics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
HCWB Nasdaq 2836 www.hcwbiologics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for HCW Biologics Inc.

HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules - Nov 19th, 2025 6:30 am
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease - Nov 18th, 2025 5:25 am
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results - Nov 14th, 2025 2:44 pm
HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer - Nov 10th, 2025 5:00 am
HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - Nov 7th, 2025 5:00 am
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment - Oct 22nd, 2025 7:00 am
HCW Biologics to Participate in the 2025 Maxim Growth Summit - Oct 16th, 2025 7:25 am
HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer - Oct 16th, 2025 7:15 am
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program - Sep 30th, 2025 6:45 am
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing - Sep 18th, 2025 7:15 am
HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development - Sep 16th, 2025 6:00 am
Wall Street Set to Open Little Changed Friday Ahead of Consumer Sentiment Report - Sep 12th, 2025 7:21 am
Consumer Sentiment, Oil Inventory Reports Set for Release as US Futures Little Changed in Friday's Premarket Session - Sep 12th, 2025 6:03 am
HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program - Sep 9th, 2025 6:00 am
BC-Most Active Stocks - Aug 25th, 2025 8:30 am
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market - Aug 25th, 2025 6:00 am
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results - Aug 18th, 2025 12:44 pm
HCW Biologics Second Quarter 2025 Earnings: US$0.90 loss per share (vs US$16.16 loss in 2Q 2024) - Aug 16th, 2025 6:18 am
Insiders Re-Evaluate Their US$3.05m Stock Purchase As HCW Biologics Falls To US$6.9m - Jul 2nd, 2025 8:27 am
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors - Jun 27th, 2025 5:45 am